101772-29-6 Usage
Description
BOC-N-ME-SER-OH, also known as N-Boc-N-methyl-L-serine, is an amino acid building block with a white to off-white solid appearance. It is used in organic synthesis and pharmaceuticals due to its unique chemical properties.
Uses
Used in Organic Synthesis:
BOC-N-ME-SER-OH is used as a precursor in organic synthesis for the development of various chemical compounds. Its unique structure allows for the creation of a wide range of molecules, making it a valuable component in the synthesis process.
Used in Pharmaceutical Industry:
BOC-N-ME-SER-OH is used as an amino acid building block in peptide synthesis. With the growing peptide drug market, the fast and reliable synthesis of peptides is of great importance. This amino acid building block plays a crucial role in the development of new and innovative peptide-based drugs.
Used in Peptide Synthesis:
BOC-N-ME-SER-OH is used as a key component in the synthesis of peptides. Its unique properties allow for the creation of specific peptide sequences, which can be used for various therapeutic applications. The use of this amino acid building block in peptide synthesis contributes to the advancement of peptide-based drug development.
Check Digit Verification of cas no
The CAS Registry Mumber 101772-29-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,1,7,7 and 2 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 101772-29:
(8*1)+(7*0)+(6*1)+(5*7)+(4*7)+(3*2)+(2*2)+(1*9)=96
96 % 10 = 6
So 101772-29-6 is a valid CAS Registry Number.
101772-29-6Relevant articles and documents
Design, synthesis, and in vitro antiplasmodial activity of 4-aminoquinolines containing modified amino acid conjugates
Srinivasarao, Kondaparla,Agarwal, Pooja,Srivastava, Kumkum,Haq,Puri, Sunil K.,Katti
, p. 1148 - 1162 (2016)
Abstract: A new series of side chain-modified 4-aminoquinolines were synthesized and screened for in vitro antiplasmodial activity against both chloroquine-sensitive (3D7) and chloroquine-resistant (K1) strains of Plasmodium falciparum. Among the series, compounds 30 and 31 showed significant inhibition of parasite growth against K1 strain of P. falciparum with IC50 values 0.28 and 0.31?μM, respectively, whereas compounds 34, 35, and 38 exhibited superior activity against K1 strain with IC50 values 0.18, 0.22, and 0.17?μM, respectively, as compared to 0.255?μM for chloroquine (CQ). All the compounds displayed good resistance factor between 1.54 and >34.48 as against 51.0 for CQ. All these analogues were found to form strong complex with hematin and inhibited the β-hematin formation in vitro, suggesting that this class of compounds act on a heme polymerization target. Overall results suggest that present series of compounds appear to be promising for further lead optimization to obtain compounds active against drug-resistant parasites. Graphical Abstract: [Figure not available: see fulltext.]
